Abstract
Objectives: To examine the relationship between multiple measures of health care costs and health utilities, quality of life, and other factors in Alzheimers Disease (AD). Research Design: Data were obtained via caregiver proxy at baseline and 3- 6- and 9-months following study entry on 421 patients with AD who participated in the CATIE-AD trial of antipsychotic medication. Spearman rank correlations and mixed models (using logged costs) were used to examine the correlates of health care costs. Measures: Health care costs include inpatient hospital, nursing home, residential care, combined institutional, outpatient, ancillary drug, and total costs. Correlates include the AD-Related Quality of Life Scale (ADRQoL) and Health Utilities Index (HUI)-III. Results: Total monthly health care costs averaged $1,205 during the study period. Each .10 increment on the HUI-III (stronger health utilities) was associated with a decrease in institutional, outpatient, and total costs of 9.7%, 6.9%, and 8.2%, respectively. Each one-point increase on the ADRQoL (better quality of life) was associated with an increase in ancillary drug and total costs of 1.7% and 2.1%. Total costs tended to be lower for female patients (β=-.325) with better physical functioning (β=-.017) but higher for less cognitively impaired individuals (β=.038). Older (β=.025), non- Hispanic Whites (β=.575) tended have higher outpatient costs, those with better physical functioning lower institutional costs (β=-.019). Drug costs tended to be lower for females (β=-.427) and higher for those with greater psychiatric symptoms (β=.016). Conclusion: The HUI-III findings suggest that health utilities could be combined with other known correlates of costs to inform resource allocation cost-effectiveness analyses associated with AD. The ADRQoL findings suggest that better quality of life may make it easier for caregivers to identify problems and/or to access and maintain certain types of health system contacts.
Keywords: Alzheimer's disease, costs, health utilities index, quality of life, correlates
Current Alzheimer Research
Title: Assessing the Relationship between Health Utilities, Quality of Life, and Health Care Costs in Alzheimers Disease: The CATIE-AD Study
Volume: 7 Issue: 4
Author(s): E.A. Miller, R.A. Rosenheck and L.S. Schneider
Affiliation:
Keywords: Alzheimer's disease, costs, health utilities index, quality of life, correlates
Abstract: Objectives: To examine the relationship between multiple measures of health care costs and health utilities, quality of life, and other factors in Alzheimers Disease (AD). Research Design: Data were obtained via caregiver proxy at baseline and 3- 6- and 9-months following study entry on 421 patients with AD who participated in the CATIE-AD trial of antipsychotic medication. Spearman rank correlations and mixed models (using logged costs) were used to examine the correlates of health care costs. Measures: Health care costs include inpatient hospital, nursing home, residential care, combined institutional, outpatient, ancillary drug, and total costs. Correlates include the AD-Related Quality of Life Scale (ADRQoL) and Health Utilities Index (HUI)-III. Results: Total monthly health care costs averaged $1,205 during the study period. Each .10 increment on the HUI-III (stronger health utilities) was associated with a decrease in institutional, outpatient, and total costs of 9.7%, 6.9%, and 8.2%, respectively. Each one-point increase on the ADRQoL (better quality of life) was associated with an increase in ancillary drug and total costs of 1.7% and 2.1%. Total costs tended to be lower for female patients (β=-.325) with better physical functioning (β=-.017) but higher for less cognitively impaired individuals (β=.038). Older (β=.025), non- Hispanic Whites (β=.575) tended have higher outpatient costs, those with better physical functioning lower institutional costs (β=-.019). Drug costs tended to be lower for females (β=-.427) and higher for those with greater psychiatric symptoms (β=.016). Conclusion: The HUI-III findings suggest that health utilities could be combined with other known correlates of costs to inform resource allocation cost-effectiveness analyses associated with AD. The ADRQoL findings suggest that better quality of life may make it easier for caregivers to identify problems and/or to access and maintain certain types of health system contacts.
Export Options
About this article
Cite this article as:
Miller E.A., Rosenheck R.A. and Schneider L.S., Assessing the Relationship between Health Utilities, Quality of Life, and Health Care Costs in Alzheimers Disease: The CATIE-AD Study, Current Alzheimer Research 2010; 7 (4) . https://dx.doi.org/10.2174/156720510791162386
DOI https://dx.doi.org/10.2174/156720510791162386 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Simulation and Performance Analysis of Tilted Time Window and Support Vector Machine Based Learning Object Ranking Method
Recent Advances in Electrical & Electronic Engineering Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Protein Tyrosine Nitration: Role in Aging
Current Aging Science Chemical and Pharmacological Aspects of Heteroaryl-Nitrones
Current Medicinal Chemistry RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD
Current Alzheimer Research Genetics of Alzheimer's Disease and Frontotemporal Dementia
Current Molecular Medicine Amyloid β-Peptide: The Inside Story
Current Alzheimer Research Molecular and Cellular Mechanisms for Alzheimers Disease:Understanding APP Metabolism
Current Molecular Medicine The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Mediterranean Diet and Risk of Dementia
Current Alzheimer Research Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Patterns of Gray and White Matter Changes in Individuals at Risk for Alzheimer’s Disease
Current Alzheimer Research Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets